Michael's mailing address filed with the SEC is 800 WEST EL CAMINO REAL, SUITE 180, MOUNTAIN VIEW, CA, 94040.
Over the last 4 years, insiders at Kinnate Biopharma have traded over 0$ worth of Kinnate Biopharma stock and bought 12,223,600 units worth 79,803,534$ . The most active insiders traders include Carl L Gordon、Advisors Llc Orbi Med Capit...、Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of 2,699,377$. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth 4,984,000$.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Kinnate Biopharma executives and other stock owners filed with the SEC include: